Basic Information
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Water Solubility | 1000.0 | mg/L | <1 | mg/ml | MSDS |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| T Max | 1.0 | h | 1 | h | DRUGBANK | |
| Clearance | 123.0 | L/h | 123.0 | L/h | apparent clearance; Oral single dose; | DRUGBANK |
| Clearance | 144.0 | L/h | 144.0 | L/h | apparent clearance; Oral multiple dose; | DRUGBANK |
| Volume of Distribution | 1674.0 | L | 1674.0 | L | Apparent volume of distribution; at steady state; | DRUGBANK |
| Volume of Distribution | 881.0 | L | 881.0 | L | Apparent volume of distribution; Multiple dose; at steady state; | DRUGBANK |
| Half-life | 5.0 | h | 4-6 | h | elimination half-life; | DRUGBANK |
| Protein Binding | 80.0 | % | 80 | % | plasma proteins; human, homo sapiens; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for adults | 150.0 | mg/day | 150 | mg/day | PO, oral; up to 24months | Orilissa | elagolix | PDR |
| Max dose for adults | 400.0 | mg/day | 400 | mg/day | PO, oral; up to 6 months | Orilissa | elagolix | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1